Aldoss I, Yang D, Aribi A, Ali H,
Sandhu K, Al Malki MM, Mei M, Salhotra A, Khaled S, Nakamura R, Snyder D, O'Donnell M, Stein AS, Forman SJ, Marcucci G, Pullarkat V.
Efficacy of the combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica. 2018 Sep;103(9):e404-e407
Aldoss I, Dadwal S, Zhang J, Tegtmeier B, Mei M, Arslan S, Al Malki MM, Salhotra A, Ali H, Aribi A,
Sandhu K, Khaled S, Snyder D, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V.
Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents. Blood Advances. 2019 Dec 10;3(23):4043-4049.
Srinagesh HK, Özbek U, Kapoor U, Ayuk F, Aziz M, Ben-David K, Choe HK, DeFilipp Z, Etra A, Grupp SA, Hartwell MJ, Hexner EO, Hogan WJ, Karol AB, Kasikis S, Kitko CL, Kowalyk S, Lin JY, Major-Monfried H, Mielke S, Merli P, Morales G, Ordemann R, Pulsipher MA, Qayed M, Reddy P, Reshef R, Rösler W,
Sandhu KS, Schechter T, Shah J, Sigel K, Weber D, Wölfl M, Wudhikarn K, Young R, Levine JE, Ferrara JLM.
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Advances 2019 Dec 10;3(23):4034-4042.
Mei M, Tsai N, Mokhtari S, Al Malki M, Ali H, Salhotra A,
Sandhu K, Khaled S, Smith E, Snyder D, Marcucci G, Forman S, Pullarkat, Stein A, Aldoss, Nakamura R.
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation. 2020 Aug;26(8):1425-1432.
Salhotra A, Yang D, Mokhtari S, Malki MMA, Ali H,
Sandhu KS, Aribi A, Khaled S, Mei M, Budde E, Snyder D, Cao T, Spielberger R, Marcucci G, Pullarkat V, Forman SJ, Nakamura R, Stein A, Aldoss I.
Outcomes of Allogeneic Hematopoietic Cell Transplantation After Salvage-Therapy With Blinatumomab in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation. 2020 Feb 5. pii: S1083-8791(20)30062-8.
Sandhu KS, Dadwal S, Yang D, Mei M, Palmer J, Salhotra A, Al Malki M, Aribi A, Ali H, Khaled S, Forman SJ, Snyder D, Nakamura R, Stein AS, Marcucci G, Aldoss I, Pullarkat V.
Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation. 2020 Dec;26(12): e322-e327.
S.C. Gergoudis, Z. DeFilipp, U. zbek,
K.S. Sandhu, A.M. Etra, H.K. Choe, C.L. Kitko, F. Ayuk, M. Aziz, J. Baez, K. Ben-David, U. Bunworasate, I. Gandhi, E.O. Hexner, W.J. Hogan, E. Holler, S. Kasikis, S.M. Kowalyk, J.Y. Lin, P. Merli, G. Morales, R. Nakamura, R. Reshef, W. Rsler, H. Srinagesh, R. Young, Y.B. Chen, J.L.M. Ferrara, J.E. Levine.
Biomarker-guided preemption of steroid-refractory graft-versus-host disease with a-1-antitrypsin, Blood Advances. Dec 2020; 4 (24): 6098–6105.